|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Tobira Therapeutics Inc. Announces Positive 24-Week Primary Analysis From Phase 2b Trial of Cenicriviroc in Treatment-Naïve HIV Infection
1/7/2013 10:30:05 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics today announced positive results from the 24-week primary analysis of Study 202, the Phase 2b study of cenicriviroc (CVC). CVC is a novel, oral, once-daily, dual CCR5/CCR2 inhibitor. Tobira is investigating CVC for the treatment of HIV-1 infected adults with CCR5-tropic virus. This 143-patient, double-blind, double-dummy, randomized, controlled Phase 2b trial (Study 202, NCT01338883) met its primary objective over 24 weeks of treatment. A similar proportion of patients treated with either 100mg or 200mg of once-daily CVC plus Truvada® (emtricitabine/tenofovir disoproxil fumarate) achieved undetectable HIV viral load (<50c/mL) at week 24 when compared to patients treated with once-daily Sustiva® (efavirenz) plus Truvada®. A favorable safety and tolerability profile was observed in CVC-treated patients.
|
|
|
|
|
|
|
|
|
|
|